PMID- 28437891
OWN - NLM
STAT- MEDLINE
DCOM- 20180216
LR  - 20191210
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 90
DP  - 2017 Jun
TI  - The therapeutic effect of nano-encapsulated and nano-emulsion forms of carvacrol 
      on experimental liver fibrosis.
PG  - 880-887
LID - S0753-3322(17)30121-X [pii]
LID - 10.1016/j.biopha.2017.04.020 [doi]
AB  - OBJECTIVE: The present study aimed to compare the therapeutic efficiency of 
      nano-encapsulated and nano-emulsion carvacrol administration on liver injury in 
      thioacetamide (TAA) treated rats. METHODS: To fulfill our target, we used sixty 
      male albino rats classified into six groups as follow: control, nano-encapsulated 
      carvacrol, nano-emulsion carvacrol, thioacetamide, treated nano-encapsulated 
      carvacrol and treated nano-emulsion carvacrol groups. Blood samples were 
      collected from all groups and the separated serum was used for analysis of the 
      following biochemical parameters; aspartate aminotransferase (AST), alanine 
      aminotransferase (ALT), S100 B protein, alpha fetoprotein (AFP) and caspase-3. 
      The levels of malondialdehyde (MDA), reduced glutathione (GSH), nitric oxide 
      (NO), monocyte chemoattractant protein-1(MCP-1) and hydroxyproline content were 
      all evaluated in liver tissue homogenate. Histopathological examinations for 
      liver tissues were also performed. RESULTS: Thioacetamide induced hepatic damage 
      in rats as revealed by the significant increase in the levels of serum ALT, AST 
      and produced oxidative stress as displayed by the significant elevation in the 
      levels of hepatic MDA and NO concomitant with a significant decrease in GSH. In 
      addition, thioacetamide significantly increased serum S100B protein, alpha 
      fetoprotein and caspase-3 along with hepatic MCP-1 and hydroxyproline; these 
      results were confirmed by the histopathological investigation. In contrast, 
      nano-encapsulated and nano-emulsion carvacrol were able to ameliorate these 
      negative changes in the thioacetamide injected rats. However, the effect of the 
      nano-encapsulated form of carvacrol was more prominent than the nano-emulsion 
      form. CONCLUSION: Nano-encapsulated and nano-emulsion carvacrol can ameliorate 
      thioacetamide induced liver injury. These results could be attributed to the 
      potential anti-inflammatory, antioxidant, and anti-apoptotic activities of 
      carvacrol in addition to the effectiveness of the encapsulation technique that 
      can protect carvacrol structure and increase its efficiency and stability. 
      Moreover, nano-encapsulation of carvacrol is more efficient than nano-emulsion.
CI  - Copyright (c) 2017 Elsevier Masson SAS. All rights reserved.
FAU - Hussein, Jihan
AU  - Hussein J
AD  - Medical Biochemistry Department, Medical Division, National Research Centre, 
      Dokki, Giza, Egypt(1).
FAU - El-Banna, Mona
AU  - El-Banna M
AD  - Medical Biochemistry Department, Medical Division, National Research Centre, 
      Dokki, Giza, Egypt(1).
FAU - Mahmoud, Khaled F
AU  - Mahmoud KF
AD  - Technology Dept., National Research Centre (NRC), Dokki, Giza, Egypt.
FAU - Morsy, Safaa
AU  - Morsy S
AD  - Medical Biochemistry Department, Medical Division, National Research Centre, 
      Dokki, Giza, Egypt(1).
FAU - Abdel Latif, Yasmin
AU  - Abdel Latif Y
AD  - Medical Biochemistry Department, Medical Division, National Research Centre, 
      Dokki, Giza, Egypt(1).
FAU - Medhat, Dalia
AU  - Medhat D
AD  - Medical Biochemistry Department, Medical Division, National Research Centre, 
      Dokki, Giza, Egypt(1).
FAU - Refaat, Eman
AU  - Refaat E
AD  - Medical Biochemistry Department, Medical Division, National Research Centre, 
      Dokki, Giza, Egypt(1).
FAU - Farrag, Abdel Razik
AU  - Farrag AR
AD  - Pathology Department, National Research Centre, Dokki, Giza, Egypt(1).
FAU - El-Daly, Sherien M
AU  - El-Daly SM
AD  - Medical Biochemistry Department, Medical Division, National Research Centre, 
      Dokki, Giza, Egypt(1). Electronic address: sm.el-daly@nrc.sci.eg.
LA  - eng
PT  - Journal Article
DEP - 20170421
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antioxidants)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cymenes)
RN  - 0 (Emulsions)
RN  - 0 (Monoterpenes)
RN  - 0 (Protective Agents)
RN  - 075T165X8M (Thioacetamide)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 9B1J4V995Q (carvacrol)
RN  - EC 2.6.1.1 (Aspartate Aminotransferases)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - EC 3.4.22.- (Caspase 3)
RN  - GAN16C9B8O (Glutathione)
SB  - IM
MH  - Alanine Transaminase/metabolism
MH  - Animals
MH  - Antioxidants/metabolism
MH  - Aspartate Aminotransferases/metabolism
MH  - Caspase 3/metabolism
MH  - Chemokine CCL2/metabolism
MH  - Cymenes
MH  - Disease Models, Animal
MH  - Emulsions/chemistry/*pharmacology
MH  - Glutathione/metabolism
MH  - Liver/drug effects/metabolism
MH  - Liver Cirrhosis/chemically induced/*drug therapy/metabolism
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Monoterpenes/*pharmacology
MH  - Nanoparticles/*chemistry
MH  - Oxidative Stress/drug effects
MH  - Protective Agents/pharmacology
MH  - Rats
MH  - Thioacetamide/pharmacology
OTO - NOTNLM
OT  - Apoptosis
OT  - Carvacrol
OT  - Inflammation
OT  - Liver fibrosis
OT  - Nano-emulsion
OT  - Nano-encapsulation
OT  - Oxidative stress
EDAT- 2017/04/26 06:00
MHDA- 2018/02/17 06:00
CRDT- 2017/04/26 06:00
PHST- 2017/01/08 00:00 [received]
PHST- 2017/03/29 00:00 [revised]
PHST- 2017/04/10 00:00 [accepted]
PHST- 2017/04/26 06:00 [pubmed]
PHST- 2018/02/17 06:00 [medline]
PHST- 2017/04/26 06:00 [entrez]
AID - S0753-3322(17)30121-X [pii]
AID - 10.1016/j.biopha.2017.04.020 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2017 Jun;90:880-887. doi: 10.1016/j.biopha.2017.04.020. Epub 
      2017 Apr 21.